Semler Scientific (SMLR) Q4 2024 earnings summary

Executive summary

• Achieved strong performance and record cash generation from healthcare operations in 2024, with a strategic focus on both core medical products and a Bitcoin treasury strategy.

• Adopted Bitcoin as the primary treasury reserve asset in May 2024, becoming the second U.S. public company to do so, and accumulated 3,192 Bitcoins valued at over $300 million.

• Market capitalization increased by more than 200% since adopting the Bitcoin strategy nine months ago.

• Achieved income from operations of $20.9 million for 2024.

• BTC Yield KPI reached 107% for 2024, reflecting accretive bitcoin acquisition relative to share count.

Financial highlights

• 2024 revenue was $56.3 million, down 17% year-over-year; Q4 revenue was $12.4 million, down 18%.

• Operating expenses for 2024 fell 23% to $35.4 million; Q4 operating expenses dropped 29% to $8.9 million.

• Income from operations was $3.5 million in Q4 2024, up 40% from the prior year.

• Net income for 2024 rose 99% to $40.9 million ($5.66 basic EPS); Q4 net income surged 592% to $29.2 million ($3.64 basic EPS), driven by unrealized bitcoin gains.

• Other income net was $29 million in Q4, including a $28.8 million gain from Bitcoin fair value changes.

Outlook and guidance

• Anticipates further revenue pressure in 2025 due to additional phase-in of 2024 CMS rate changes.

• Priority for 2025 is to minimize declines in QuantaFlo revenue while supporting innovation and growth in cardiovascular disease operations.

• Committed to expanding bitcoin holdings and supporting healthcare innovation.

• Pursuing new 510(k) clearance for QuantaFlo with expanded indications.